Benefits
Supports low back comfort
In a four week randomized trial, adults having a flare of long standing low back pain who took a standardized extract providing 240 mg of salicin daily were more often pain free without rescue medication in the final week than those on placebo, and 120 mg gave an intermediate result. The benefit in the higher dose group was already visible after one week rather than building slowly. These were patients with a diagnosed pain condition studied under supervision, so this describes what the extract did in that trial; willow bark is not a treatment for a back condition, and back pain that is severe or persistent needs a clinical assessment.
Mixed results for everyday joint comfort
The evidence here is genuinely split. A two week trial in 78 adults with hip or knee osteoarthritis found a small advantage over placebo on the pain portion of the WOMAC index, 6.5 mm on a 100 mm scale with a confidence interval running from 0.2 to 12.7 mm and a p value of 0.047, which its authors described as a moderate analgesic effect. A later trial that was larger and longer, 127 adults over six weeks at the same 240 mg salicin dose, found no significant advantage for willow bark over placebo, while the diclofenac arm in that same trial clearly beat placebo, showing the study could detect a real effect. A 2023 meta analysis pooling six randomized trials in arthritis did find an overall pain benefit, but its authors judged their own certainty inadequate because of bias in the underlying trials. Anyone with diagnosed arthritis should be working with a clinician rather than substituting a supplement.
More than salicin alone, so far shown only in laboratory and animal studies
This point matters more than it first appears. When investigators measured what actually reaches the bloodstream, a dose of 240 mg salicin produced a salicylic acid exposure equivalent to only about 87 mg of aspirin, far below an anti-inflammatory dose, and they concluded that salicylic acid formation alone is unlikely to explain willow bark's effects. The flavonoids and polyphenols in the bark are the leading candidate for the remainder, and laboratory and animal work reports that willow bark extract lowers inflammatory signals including tumor necrosis factor alpha and nuclear factor kappa B. That work has not been carried through to people. The only human trial to measure circulating inflammatory cytokines gave 20 healthy adults a three herb beverage containing willow bark for four weeks and found no significant change, so the anti-inflammatory description rests on laboratory and animal work rather than on a demonstrated effect in people.
Long history of traditional use
Willow bark has been chewed and brewed for pain and fever for centuries, and it is the plant from which the salicylate chemistry that produced aspirin was first drawn. Traditional use establishes that a plant was used, not that it works or that it is safe at modern doses. Here the tradition also carries the warning, because the reason it exists is the salicylate content, which is exactly why willow bark is not a gentler alternative for someone who has been told to avoid aspirin.
Standardization is what makes a product comparable to the studies
The randomized trials behind this evidence used extracts standardized to a stated daily amount of salicin, either 120 or 240 mg, given for two to six weeks. That detail is easy to lose on a shelf. Plain milled bark, or an extract listing only a total milligram weight with no salicin figure, cannot be assumed to deliver what the studies delivered, and chemical analysis of two willow bark preparations that had themselves been used in clinical trials found several clear compositional differences between them. Reading the salicin figure rather than the bark weight is the only way to know what you are taking.
Mechanism of action
Salicin to salicylic acid conversion
Gut bacteria hydrolyze salicin to saligenin, which is absorbed and oxidized in the liver to salicylic acid, the same active metabolite as that produced from acetylsalicylic acid (aspirin). This conversion is the reason willow bark carries aspirin's cautions. It is not, however, a complete explanation of how the extract works: when the resulting blood levels were measured directly, a 240 mg salicin dose produced salicylic acid exposure equivalent to roughly 87 mg of aspirin, and the investigators concluded that salicylic acid formation alone is unlikely to account for the analgesic effects seen in trials.
Cyclooxygenase pathway modulation
Salicylic acid and willow bark constituents can inhibit cyclooxygenase enzymes and reduce prostaglandin synthesis in inflammatory cells, contributing to reductions in pain signaling and inflammatory mediator output. This step is described from laboratory and animal work and has not been demonstrated in people taking willow bark. The animal results are not uniform either: in rat models of acute and chronic inflammation a standardized willow bark extract suppressed prostaglandins and inflammatory cytokines, while in dairy calves given oral willow bark at three doses prostaglandin E2 did not fall at any dose, although a conventional anti-inflammatory drug given in the same study did lower it.
Polyphenol and flavonoid activity
Willow bark flavonoids and polyphenols show antioxidant and anti-inflammatory activity in laboratory studies, which may contribute additional support beyond what is attributable to salicin alone.
Lower salicylate exposure than an analgesic dose of aspirin
Measured in ten healthy volunteers, a standardized extract supplying 240 mg salicin in two divided doses produced peak serum salicylic acid averaging 1.2 mg per liter, reached within two hours rather than slowly, with total exposure equivalent to about 87 mg of acetylsalicylic acid. That is far below the levels reached after analgesic doses of aspirin. This cuts both ways for a buyer: willow bark is not secretly delivering a large aspirin dose, and it also should not be relied on to do what an aspirin dose does.
Clinical trials
Randomized, double-blind, placebo-controlled trial; 4 weeks; willow bark extract providing 120 or 240 mg salicin daily vs placebo.
210 adults with an exacerbation of chronic low back pain, all reporting current pain of at least 5 out of 10.
In the final week, 27 of 65 people (39 percent) taking 240 mg salicin were pain free without rescue medication, against 15 of 67 (21 percent) at 120 mg and 4 of 59 (6 percent) on placebo, with a p value below 0.001. That graded ordering of the three rates is what the dose-response statement rests on. The high dose response was evident after one week, and placebo participants needed the rescue drug, tramadol, significantly more often in every week of the trial. Two limits are worth stating plainly: participants had exacerbations of long standing back pain rather than acute injuries, and one person suffered a severe allergic reaction that the investigators considered possibly caused by the extract.
Randomized, double-blind, placebo-controlled trial; 2 weeks; standardized willow bark extract providing 240 mg salicin daily.
78 adults with osteoarthritis of hip or knee.
On the WOMAC pain dimension the willow bark group improved by 6.5 mm more than placebo, with a 95 percent confidence interval of 0.2 to 12.7 mm and a p value of 0.047, so the result cleared the significance threshold only narrowly. Pain fell 14 percent from baseline on the extract while rising 2 percent on placebo, and the authors described the effect as moderate and the extract as well tolerated. Set beside the larger six week trial that found no benefit at the same dose, this is best read as a positive but fragile result rather than a settled one.
Systematic review published in 2009, covering randomized clinical trials of Salix-based preparations across musculoskeletal pain conditions. Seven manuscripts were identified, reporting four confirmatory and four exploratory trials, with duplicate reports of the same trial data excluded.
Adults with low back pain, osteoarthritis, or other musculoskeletal pain syndromes.
The reviewers found moderate evidence for ethanolic willow bark extract in low back pain, where a dose dependent effect appeared not inferior to rofecoxib, conflicting results in osteoarthritis, and no significant effect in rheumatoid arthritis in a trial they called grossly underpowered. All trials used ethanolic extracts at up to 240 mg salicin daily for up to six weeks, and only minor adverse events were reported. One caveat on independence: this review's senior author also led the low back pain trial it rates most favorably. Two later syntheses have revisited the question. A 2014 Cochrane review graded the low back pain evidence as moderate quality across two trials and 261 participants, and a 2023 meta analysis of six randomized trials in arthritis found a pooled pain benefit while judging its own certainty inadequate.